Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
Eligible age
18–65 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.
Sponsor: University of Texas Southwestern Medical Center
You may qualify if…
- ✓ Adults aged 18-65 with confirmed psoriatic arthritis based on CASPAR criteria.
- ✓ Ability to provide informed consent and comply with study procedures.
- ✓ Patients with plaque psoriasis BSA\>3% OR PsA with \[SJC\>2 AND TJC \>3\] despite stable background anti-TNF therapy for at least 6 months, with or without csDMARDs (i.e MTX, leflunomide, sulfasalazine, hydroxychloroquine).
- ✓ Concurrent use of 1 csDMARD, and/or NSAID, and/or oral glucocorticoid is permitted but not required during the study. If such treatment was administered, then participants must meet the following requirements:
- ✓ If on csDMARD (methotrexate \[MTX\], sulfasalazine \[SSZ\], leflunomide \[LEF\], hydroxychloroquine \[HCQ\]), the participant must have been on it for at least 12 weeks and be on a stable dose for at least 28 days prior to Day 1.
- ✓ If on MTX, the route of administration and dose must be stable and the dose must be ≤ 25 mg/week.
- ✓ If on SSZ, the dose must be ≤ 3 g/day.
- ✓ If on HCQ, the dose must be ≤ 400 mg/day.
You may not qualify if…
- ✕ History of failure of more than two anti-TNF therapies, prior history of failure of TYK2 and JAK inhibitors.
- ✕ History of prior allergic reaction or intolerance to deucravacitinib.
- ✕ History of primary failure of anti-IL17, anti-IL23 is excluded. Note that prior exposure to these agents is allowed for reasons other than primary failure, eg intolerance, insurance / access issues, etc).
- ✕ Systemic agents other than anti-TNF or csDMARD (ie. MTX, leflunomide, sulfasalazine, hydroxychloroquine) must have ceased \> 6 months prior to baseline.
- ✕ Doses or glucocorticoids \>15mg daily prednisone or equivalent.
- ✕ Severe cardiovascular, hepatic, or renal impairment.
- ✕ History or evidence of outpatient active infection and/or febrile illness within 14 days prior to Day 1.
- ✕ History of serious bacterial, fungal, or viral infection requiring hospitalization or parenteral antimicrobial treatment (eg, antibiotics antiviral, antifungal, or antiparasitic agents) within 60 days prior to Day 1.
Where it's recruiting
Dallas
Source: ClinicalTrials.gov · NCT07280702 · last updated 2026-09-01